Evidence map›Paper›PMID 34867872›Full record

ArticleFrontiers in microbiology2021

Antiviral Activity of CD437 Against Mumps Virus.

Fumihiro Kato, Yuichiro Nakatsu, Keiko Murano, Aika Wakata, Toru Kubota, Takayuki Hishiki, Toshiyuki Yamaji, Minoru Kidokoro, Hiroshi Katoh, Makoto Takeda

Open access · goldAbstract read
In one paragraph

Article in Frontiers in microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Fumihiro KatoDepartment of Virology III, National Institute of Infectious Diseases, Tokyo, Japan.
Yuichiro NakatsuDepartment of Virology III, National Institute of Infectious Diseases, Tokyo, Japan.
Keiko MuranoDepartment of Virology III, National Institute of Infectious Diseases, Tokyo, Japan.
Aika WakataDepartment of Virology III, National Institute of Infectious Diseases, Tokyo, Japan.
Toru KubotaDepartment of Virology III, National Institute of Infectious Diseases, Tokyo, Japan.
Takayuki HishikiDepartment of Microbiology, Kanagawa Prefectural Institute of Public Health, Chigasaki, Japan.
Toshiyuki YamajiDepartment of Biochemistry and Cell Biology, National Institute of Infectious Diseases, Tokyo, Japan.
Minoru KidokoroDepartment of Virology III, National Institute of Infectious Diseases, Tokyo, Japan.
Hiroshi KatohDepartment of Virology III, National Institute of Infectious Diseases, Tokyo, Japan.
Makoto TakedaDepartment of Virology III, National Institute of Infectious Diseases, Tokyo, Japan.
National Institute of Infectious Diseases · JPKanagawa Prefectural Institute of Public Health · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Many efforts have been dedicated to the discovery of antiviral drug candidates against the mumps virus (MuV); however, no specific drug has yet been approved. The development of efficient screening methods is a key factor for the discovery of antiviral candidates. In this study, we evaluated a screening method using an

Indexed as

antiviral compoundCD437knockout cellmumps virusscreening

Identifiers

PMID34867872
PMCPMC8636907
OpenAlexW3211764636

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.